Filing Flows › Aktis Oncology (AKTS) › Q1 2026
Aktis Oncology (AKTS) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 11, 2026
Aktis Oncology (AKTS) reported revenue of $3.2M for the first quarter 2026 (Q1 2026), +123% from a year earlier. Operating margin was -703.6%, net loss $18.3M (567.9% of revenue).
Aktis Oncology, Q1 2026: revenue $3.2M (+123% year over year), operating margin -703.6%, net loss $18.3M, operating cash flow −$24.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.2M | — | +123% |
| Operating profit | −$22.7M | — | — |
| Net earnings | −$18.3M | — | — |
| Operating cash flow | −$24.2M | — | — |
What changed
Revenue was $3.2M in Q1 2026, up 123% year over year.
Operating costs exceeded revenue by $22.7M, an operating margin of -703.6%. Total costs grew 32% against revenue growth of 123%. The fastest-growing cost line was General & admin (+58%). The quarter ended with a net loss of $18.3M. Non-operating items added $4.4M, -24% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$24.2M. Non-cash charges added back $652K of depreciation and amortization and $3.0M of share-based compensation. Working capital and other items used $9.6M. Capital expenditures of $1.9M exceeded it, leaving free cash flow of −$26.1M.
Questions
What was Aktis Oncology's revenue in the first quarter 2026?
Aktis Oncology (AKTS) reported revenue of $3.2M for the first quarter 2026 (Q1 2026), +123% from a year earlier.
Was Aktis Oncology profitable in the first quarter 2026?
Operating loss was $22.7M (-703.6% of revenue) and net loss $18.3M.
Source: Aktis Oncology 10-Q on SEC EDGAR.